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AAPM Task Group 119 has produced quantitative confidence limits as baseline expectation values
for IMRT commissioning. A set of test cases was developed to assess the overall accuracy of
planning and delivery of IMRT treatments. Each test uses contours of targets and avoidance struc-
tures drawn within rectangular phantoms. These tests were planned, delivered, measured, and
analyzed by nine facilities using a variety of IMRT planning and delivery systems. Each facility had
passed the Radiological Physics Center credentialing tests for IMRT. The agreement between the
planned and measured doses was determined using ion chamber dosimetry in high and low dose
regions, film dosimetry on coronal planes in the phantom with all fields delivered, and planar
dosimetry for each field measured perpendicular to the central axis. The planar dose distributions
were assessed using gamma criteria of 3%/3 mm. The mean values and standard deviations were
used to develop confidence limits for the test results using the concept confidence limit= mean
+1.96. Other facilities can use the test protocol and results as a basis for comparison to this group.5359 5359Med. Phys. 36 „11…, November 2009 0094-2405/2009/36„11…/5359/15/$25.00 © 2009 Am. Assoc. Phys. Med.
Locally derived confidence limits that substantially exceed these baseline values may indicate the
5360 Ezzell et al.: Report from AAPM Task Group 119: IMRT commissioning 5360need for improved IMRT commissioning. © 2009 American Association of Physicists in Medicine.
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I. INTRODUCTION
The 2003 “Guidance Document” on IMRT1 noted that “This
complex but promising treatment modality is rapidly prolif-
erating in both academic and community practice settings.”
The intervening years have seen the use of IMRT become
commonplace. It is reported that approximately 30%–60% of
cancer patients in the United States are currently being
treated with IMRT.2 However, there is evidence that IMRT
treatments may not always be as accurate as practitioners
believe. In 2008, the Radiological Physics Center RPC re-
ported that of the 250 irradiations of a head and neck phan-
tom as part of an IMRT credentialing process, 71 28% had
failed to meet accuracy criteria of 7% for dose in a lowMedical Physics, Vol. 36, No. 11, November 2009gradient.3 This is a sobering statistic, especially considering
that this is a sample of those institutions that felt confident
enough in their IMRT planning and delivery process to apply
for credentialing and presumably expected to pass.
This experience strongly suggests that some clinics have
not adequately commissioned their planning and delivery
systems for IMRT. By “commissioning,” we mean the initial
verification by phantom studies that treatments can be
planned, prepared, and delivered with sufficient accuracy.
Commissioning is different from per-patient phantom mea-
surements for quality assurance purposes. In the latter case,
the doses in the phantom are not the same as the doses pre-
dicted for the patient, and so are not complete tests of the
total planning and delivery chain. Commissioning studies are
best done by defining target and normal structure shapes on
CT images of the dosimetry phantom, planning the treat-
ment, and then comparing the measured dose in the phantom
to the planned dose from the computer system. Commission-
ing studies should mimic the types of target and structure
geometries along with the target doses and dose constraints
that are likely to be encountered in the clinic. Commission-
ing studies should also be performed with particular care to
minimize measurement uncertainties, which should be quan-
tified. Differences between calculations and measurements
can only be meaningfully evaluated if the uncertainties are
understood.
The commissioning process was discussed in general
terms in the 2003 Guidance Document.1 Task Group 119 of
the American Association of Physicists in Medicine AAPM
was charged with expanding that guidance document. In this
work, TG119 has focused on the problem of quantifying the
overall performance of an IMRT system and determining
reasonable confidence limits CLs for assessing the ad-
equacy of the dosimetric commissioning. This report does
not deal with many other important aspects of IMRT quality
assurance, such as additional periodic QA of multileaf colli-
mators, which are left for future work. The report from Task
Group 142 Working Group on Recommendations for Radio-
therapy External Beam Quality Assurance,23 will address
some of these issues. The report from Task Group 120 Writ-
ing Group on IMRT Metrology, also in preparation, will
address specific issues related to measurement tools and
analysis methods for IMRT.
The task group first developed a specific set of tests for
IMRT commissioning that are representative of common
clinical treatments. While not exhaustive, these tests pose a
range of optimization problems requiring simple to complex
modulation patterns. These represent total system checks of
different types and levels of complexity. Differences between
measurement and prediction may be caused by measurement
TABLE I. List of participating institutions and the systems utilized. Manufacturer’s identifications are listed below the table. “DMLC” refers to dynamic MLC,
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and limitations in the dose delivery mechanisms. These tests
do not serve to distinguish between these sources but test the
overall accuracy of the IMRT system.
Each test includes target and normal structure shapes that
a physicist can create on a simple slab phantom. Each test
includes a specification of dose goals for the IMRT planning
and the beam arrangement to be used. Each test also specifies
the measurements to be taken to test the accuracy of the dose
delivery and what is to be reported.
Members of the group have planned and delivered the
treatments using the local planning and delivery systems and
then assessed the resulting doses using broadly available do-
simetry tools. The goal was to produce quantitative examples
of the degree of agreement that should be expected for such
tests, and thus provide the medical physics community with
a useful set of benchmark data. Institutions that do similar
tests and achieve similar results could then have more con-
fidence that their system’s performance is clinically accept-
able, at least for the types of treatments modeled by the
commissioning tests. Conversely, and we hope, helpfully, in-
stitutions with worse results can use these tests to refine their
planning and delivery systems.
This study has quantified the “degree of agreement that
should be expected” using the concept of “confidence limit”
as proposed by Venselaar et al.4 and refined by Palta et al.5
Whenever a measurement is made and compared to a calcu-
lation, one can expect some difference to be seen. If the
difference is within a reasonable confidence limit, then the
result can be considered acceptable. This task group has es-
tablished confidence limits for different types of measure-
ments by combining data from the participating institutions.
Each of the institutions that have participated in this study
has passed the RPC IMRT credentialing test using the RPC’s
head and neck dosimetry phantom.
The confidence limit is based on the average difference
between measured and expected values for a number of mea-
surements of comparable situations systematic difference
summed with the standard deviation of the differences mul-
tiplied by some factor random difference. In the formula-
sometimes called “sliding window.” “SMLC” refers to static MLC, sometim
CA; Siemens: Siemens AG, Healthcare Sector, Erlangen, Germany; Elekta
TOMOTHERAPY: TomoTherapy Inc., Madison, WI.
Institution Acc
Mayo Clinic Arizona Varia
Thomas Jefferson University Hospital Elekta
Robert Wood Johnson University Hospital Varia
Memorial Sloan Kettering Cancer Center Varian
Karmanos Cancer Center/Wayne State University Varia
Karmanos Cancer Center/Wayne State University Tomothe
University of California at San Francisco Siemen
University of Florida Elekta
Virginia Commonwealth University Varian
Charleston Radiation Therapy Consultants SiemeMedical Physics, Vol. 36, No. 11, November 2009tion of Palta et al., the CL is the sum of the absolute value of
the average difference and the standard deviation of the dif-
ferences multiplied by a factor of 1.96 CL
= mean deviation+1.96 SD Palta et al. used the symbol 
for CL. In this formulation that is based on the statistics of
a normal distribution, it is to be expected that 95% of the
measured points will fall within the confidence limit. In this
TG-119 study, the set of measurements for the group has
been combined and analyzed in this fashion to provide a
confidence limit for IMRT commissioning measurements. In
order to use these benchmark data, a facility would perform
a similar set of measurements, determine the local systematic
and random variation from the expected values, calculate the
local confidence limit using the same formulation, and see if
it is similar to that from this task group. Note that the con-
fidence limit will likely be dominated by the standard devia-
tion term with its multiplier of nearly 2. However, should the
facility find a tight distribution around a large mean differ-
ence, then the reason for that difference can very likely be
found and the result improved.
II. METHODS AND MATERIALS
Table I lists the institutions participating in the study,
along with the planning system and the delivery system used
by each.
II.A. Phantoms
Institutions were instructed to choose a phantom in which
to do the planning and measurements, following these speci-
fications. The phantom should permit point measurements
e.g., ion chamber and planar dose measurements e.g., film
to be done on coronal planes. The phantom should consist of
slabs of water-equivalent plastic, typically squares or rect-
angles 20–30 cm on a side, with a total thickness of about
15–20 cm, so that a chamber at its center is 7.5–10 cm below
the anterior surface. Note that the phantom shown in Figs.
1–5 has a different type of “water-equivalent” plastic used
for the central section that is apparent because of the narrow
CT imaging window used when the images were captured.
alled “step and shoot” Varian, ECLIPSE: Varian Medical Systems, Milpitas,
: Elekta Inc., Norcross, GA; PINNACLE: Philips Healthcare, Andover, MA;
or Delivery technique Planning system
X DMLC ECLIPSE V7.5
rgy S SMLC CMS XIO V3.1
X DMLC ECLIPSE V7.5
ogy DMLC In-house
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central measurement plane, so that the film response can be
normalized to the chamber. Each institution scanned its own
phantom for planning and measurements. The plans were
done either on that phantom with the structures outlined on it
or on a downloaded CT study and then transferred to the
local phantom for measurement, in a manner similar to per-
forming patient quality assurance measurements.
II.B. Chamber measurements
Institutions were instructed to choose an ionization cham-
ber suitable for IMRT commissioning and QA studies in the
department. This typically would be smaller than a Farmer-
type chamber, such as a 0.125 cm3 scanning chamber. The
chamber measurements were to be made with all fields irra-
diating the phantom using the planned gantry and collimator
angles. For most of the tests, measurements were to be made
in at least two locations, one in the target and one in a low
dose avoidance structure. The doses were expected to be at
least 30 cGy, so issues with very low dose measurements
would not arise.
Conversion of chamber reading to dose was to be done by
first irradiating the phantom with parallel-opposed 1010
fields arranged isocentrically and establishing the ratio of
reading to planned dose in that geometry. This was done in
order to reduce the effects of daily linac output variations
and differences between the phantom and liquid water. The
institution with the tomotherapy device measured absolute
FIG. 1. Dose profile through central plane for bands. The lower curves are
the individual contributions from each subfield band; the upper curve is the
summation.Medical Physics, Vol. 36, No. 11, November 2009doses for each delivered plan using ND,w
Co-60 and kQ values for
chambers calibrated at an accredited dosimetry calibration
laboratory.
II.C. Composite film measurements
Each test called for a film to be placed in at least one
coronal plane and to be exposed to all fields irradiating the
phantom with the planned gantry and collimator angles. In-
stitutions were expected to use their most accurate protocols
for film dosimetry. Dose distributions were analyzed using
gamma criteria6 of 3% dose and 3 mm distance to agreement.
The planar dose distributions obtained with the film could be
normalized to the dose measured with the chamber at a suit-
able point in a high dose, low gradient region. The film
analysis was done with the software tools available at each
institution. The gamma analysis was to be restricted to re-
gions to avoid those of very low dose; this was done in one
of two ways. If the software defined the region of interest
using a threshold dose, then that was set to 10% of the maxi-
mum dose. If the software required a rectangular region of
interest to be defined, then that was taken to be the jaw
FIG. 2. Multitarget structures: Central target, superior target, and inferior
target. These three cylindrical targets are stacked along the axis of rotation.
Each has a diameter of approximately 4 cm and length of 4 cm. Coronal and
transverse views are shown.
5363 Ezzell et al.: Report from AAPM Task Group 119: IMRT commissioning 5363settings for the field at gantry 0° or 180°. This restriction was
done because the percentage of points that pass the gamma
criteria can depend on the region chosen and the details of
how low dose points are handled in the algorithm imple-
mented in the particular software used.
II.D. Per-field measurements
Each institution was asked to evaluate the dose distribu-
tion produced by each field individually using the dosimetry
system available, which was either film, detector array, or
EPID. Gamma criteria of 3% dose and 3 mm distance to
agreement were used and the region of interest was specified
as above: Either 10% dose threshold or a region of interest
determined by the jaw settings.
Five of the institutions performed these measurements us-
ing the MAPCHECK diode array device Sun Nuclear Corpo-
ration, Melbourne, FL.7 They agreed on a common set of
user preferences in order to standardize the analysis to the
extent possible. These choices with brief explanation were
absolute dose measured doses were not scaled to some nor-
malization value, 10% threshold the region of interest was
defined by the isodose line representing 10% of maximum
dose,11 Van Dyk percentage difference12 the percentage dif-
ference in dose was with respect to the maximum point in the
region, not the local point, and applied measurement uncer-
FIG. 3. Mock prostate Structures: The prostate CTV, PTV, rectum, and blad-
der. The prostate CTV is roughly ellipsoidal with RL, AP, and SI dimensions
of 4.0, 2.6, and 6.5 cm, respectively. The prostate PTV is expanded 0.6 cm
around the CTV. The rectum is a cylinder with diameter of 1.5 cm that abuts
the indented posterior aspect of the prostate. The PTV includes about 1/3 of
the rectal volume on the widest PTV slice. The bladder is roughly ellipsoidal
with RL, AP, and SI dimensions of 5.0, 4.0, and 5.0 cm, respectively, and is
centered on the superior aspect of the prostate. Transverse and coronal views
are shown.Medical Physics, Vol. 36, No. 11, November 2009tainty a presumed measurement error of about 1% is in-
cluded in the analysis, so that a nominal 3% dose difference
can be 4%. The plan and measurement data from these in-
stitutions were sent to one location for analysis using version
MAPCHECK 3.04. This selection does not imply endorsement
of either this particular device or this particular set of param-
eter options for use in clinical evaluations.
II.E. Test suite: Planning conditions and measurement
specifications
Two preliminary tests with simple fields irradiating the
phantom were requested to demonstrate the reliability of the
assessment system for non-IMRT dose delivery, followed by
five tests of IMRT plans with increasing complexity. The
dose goals for the IMRT plans were expressed in total doses
with the daily dose to be 180–200 cGy. The volumes for the
IMRT plans could be either drawn de novo by the institution
or downloaded as DICOM-RT data from a central server and
transferred to the scans of the institution’s phantom. These
tests were all performed at 6 MV, which was an energy avail-
able to all the participating institutions.
II.E.1. Test P1: AP:PA
• Calculate a simple parallel-opposed irradiation of the
phantom using AP:PA 1010 fields to a dose of 200
cGy to the isocenter, placed at the phantom midline.
• Measure the central dose with the chamber and the dose
distribution on the central plane with film.
FIG. 4. Mock head/neck structures: HN PTV, cord, and parotid glands. The
PTV is retracted from the skin by 0.6 cm. There is a gap of about 1.5 cm
between the cord and the PTV. The parotid glands are to be avoided and are
at the superior aspect of the PTV. Transverse and 3D views are shown.
TABLE II. Treatment plan statistics for multitarget.
5364 Ezzell et al.: Report from AAPM Task Group 119: IMRT commissioning 5364• Use this chamber measurement to set the dose/chamber
reading ratio for subsequent tests.
• Analyze the film dosimetry and report the fraction of
points passing the gamma criteria.
II.E.2. Test P2: Bands
• Calculate a parallel-opposed irradiation of the phantom
using a series of AP:PA fields to create a set of five
bands, 3 cm wide, receiving doses from roughly 40 to
200 cGy Fig. 1. This could be done using asymmetric
jaws or static MLC fields.
• Measure the central dose with the chamber and the dose
distribution on the central plane with the film. Analyze
the film dosimetry and report the fraction of points
passing the gamma criteria.
II.E.3. Test I1: Multitarget
II.E.3.a. Structures. Three cylindrical targets are stacked
along the axis of rotation. Each has a diameter of approxi-
mately 4 cm and length of 4 cm Fig. 2. They are to receive
different doses, with the central target to receive the largest
dose per fraction. The superior target was to receive 50% of
that and the inferior 25%.
II.E.3.b. Dose goals used for planning. The dose goals
used for planning were expressed in terms of dose to 99% of
FIG. 5. CShape structures: CShape PTV and core. The center core is a
cylinder 1 cm in radius. The gap between the core and the PTV is 0.5 cm, so
the inner arc of the PTV is 1.5 cm in radius. The outer arc of the PTV is 3.7
cm in radius. The PTV is 8 cm long and the core is 10 cm long. Transverse
and 3D views are shown.Medical Physics, Vol. 36, No. 11, November 2009the volume D99 and dose to 10% of the volume D10 for
the three targets. Table II includes the specific numerical
goals.
II.E.3.c. Beam arrangement.
• 6 MV, 7 fields at 50° intervals from the vertical e.g.,
0°, 50°, 100°, 150°, 310°, 260°, 210°.
II.E.3.d. Chamber measurement points.
• Isocenter, middle of the central target.
• Center of the other two targets.
II.E.3.e. Film measurement.
• Midphantom.
II.E.4. Test I2: Mock prostate
II.E.4.a. Structures. The prostate CTV is roughly ellipsoi-
dal, with posterior concavity, with RL, AP, and SI dimen-
sions of 4.0, 2.6, and 6.5 cm, respectively. The prostate PTV
is expanded 0.6 cm around the CTV.
The rectum is a cylinder with diameter of 1.5 cm that
abuts the indented posterior aspect of the prostate. The PTV
includes about 1/3 of the rectal volume on the widest PTV
slice. The bladder is roughly ellipsoidal with RL, AP, and SI
dimensions of 5.0, 4.0, and 5.0 cm, respectively, and is cen-
tered on the superior aspect of the prostate Fig. 3.
II.E.4.b. Dose goals used for planning. For the prostate
PTV, dose goals were specified as D95 and D5. For rectum
and bladder, D30 and D10 were used. Table III includes the
specific numerical goals.
II.E.4.c. Beam arrangement.
• 6 MV, seven fields at 50° intervals from the vertical.
II.E.4.d. Chamber measurement points.
• Isocenter, in the mid-PTV.
Planning parameter
Plan goal
cGy
Mean
cGy
Standard deviation
cGy
Coefficient
of variation
Central target D99 5000 4955 162 0.033
Central target D10 5300 5455 173 0.032
Superior target D99 2500 2516 85 0.034
Superior target D10 3500 3412 304 0.089
Inferior target D99 1250 1407 185 0.132
Inferior target D10 2500 2418 272 0.112
TABLE III. Treatment plan statistics for mock prostate.
Planning parameter
Plan goal
cGy
Mean
cGy
Standard deviation
cGy
Coefficient
of variation
Prostate D95 7560 7566 21 0.003
Prostate D5 8300 8143 156 0.019
Rectum D30 7000 6536 297 0.045
Rectum D10 7500 7303 150 0.020
Bladder D30 7000 4394 878 0.200
Bladder D10 7500 6269 815 0.130
TABLE IV. Treatment plan statistics for mock head and neck. TABLE V. Treatment plan statistics for CShape easier.
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II.E.4.e. Film measurement.
• Midphantom.
II.E.5. Test I3: Mock head/neck
II.E.5.a. Structures. The volumes for the head/neck HN
case were first drawn on a scan of an anthropomorphic phan-
tom and then transferred to the rectangular phantom. The HN
PTV includes all anterior volume from the base of the skull
to the upper neck, including the posterior neck nodes. The
PTV is retracted from the skin by 0.6 cm. There is a gap of
about 1.5 cm between the cord and the PTV. The parotid
glands are to be avoided and are at the superior aspect of the
PTV Fig. 4.
II.E.5.b. Dose goals used for planning. For the head and
neck PTV, dose goals were specified as D99, D90, and D20.
For normal structures, D50 was used for parotid and maxi-
mum dose was used for cord. Table IV includes the specific
numerical goals.
II.E.5.c. Beam arrangement.
• 6 MV, 9 fields at 40° intervals from the vertical.
II.E.5.d. Chamber measurement points.
• Isocenter, in the mid-PTV.
• 4.0 cm posterior, midspinal cord.
II.E.5.e. Film measurements.
• Midphantom, includes parotids.
• 4.0 cm posterior, through cord.
II.E.6. Tests I4 and I5: Cshape
II.E.6.a. Structures. The target is a CShape that surrounds
a central avoidance structure. The center core is a cylinder 1
cm in radius. The gap between the core and the PTV is 0.5
cm, so the inner arc of the PTV is 1.5 cm in radius. The outer
arc of the PTV is 3.7 cm in radius. The PTV is 8 cm long and
the core is 10 cm long Fig. 5.
Two versions of the problem are given. In the easier, the
central core is to be kept to 50% of the target dose. In the
harder, the central core is to be kept to 20% of the target
dose. This latter goal is probably not achievable and tests a
system that is being pushed very hard.
II.E.6.b. Dose goals for planning (easier version and
harder version). For the CShape PTV, dose goals were speci-
fied as D95 and D10. For the core normal structure, D10 was
Planning parameter
Plan goal
cGy
Mean
cGy
Standard deviation
cGy
Coefficient
of variation
PTV D90 5000 5028 58 0.013
PTV D99 4650 4704 52 0.011
PTV D20 5500 5299 93 0.018
Cord maximum 4000 3741 250 0.067
Parotid D50 2000 1798 184 0.102Medical Physics, Vol. 36, No. 11, November 2009used. Table V includes the specific numerical goals for the
easier version and Table VI includes those for the harder
version.
II.E.6.c. Beam arrangement.
• 6 MV, 9 fields at 40° intervals from the vertical.
II.E.6.d. Chamber measurement points.
• Central core.
• Mid-PTV, 2.5 cm anterior to isocenter.
II.E.6.e. Film measurements.
• Midphantom.
• Mid-PTV, 2.5 cm anterior to isocenter.
III. RESULTS
III.A. Planning results
The statistics for the plans from institutions for test I1
multitarget, test I2 mock prostate, test I3 mock head and
neck, test I4 CShape easier, and test I5 CShape harder
are listed in Tables II–VI, respectively. In these tables, the
notation “D99” means the dose covering 99% of the volume.
The planning instructions did not specify a minimum cal-
culation grid size. Participants reported using grid intervals
ranging from 0.1 to 0.4 cm.
III.B. Measurement results
III.B.1. Results for preliminary test P2: Bands
Six of the institutions reported ion chamber results for the
band test. These ranged from 1.3% more than predicted to
0.9% less with a mean of 0.3% more. Four of the institutions
reported gamma results from film for the bands test with
gamma pass rates ranging from 98.3% to 99.4% with a mean
of 99.1%.
III.B.2. Ion chamber results
The results of the ion chamber measurements are shown
in Tables VII–X. In subsequent tables, the facilities are iden-
tified by letter only, not corresponding to the order by which
Planning parameter
Plan goal
cGy
Mean
cGy
Standard deviation
cGy
Coefficient
of variation
PTV D95 5000 5010 17 0.003
PTV D10 5500 5440 52 0.010
Core D10 2500 2200 314 0.141
TABLE VI. Treatment plan statistics for CShape harder.
Planning Parameter
Plan goal
cGy
Mean
cGy
Standard deviation
cGy
Coefficient
of variation
PTV D95 5000 5011 16.5 0.003
PTV D10 5500 5702 220 0.039
Core D10 1000 1630 307 0.188
TABLE VII. High dose point in the PTV measured with ion chamber: measured dose
easur
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obtained with averaged values over a number of points
within the chamber volume for institutions A–C and G–I.
Institution D used a single point at the chamber center. For E
and F one institution with two planning/delivery systems,
one point prediction was used, but the variation within the
chamber volume was inspected and found to be 1% within
the PTV region and 2% within the OAR. For institution J,
the chamber volume was so small that a single point predic-
tion was deemed sufficiently accurate. The difference be-
tween the measured and planned doses are expressed as a
ratio of the prescription dose instead of the predicted local
dose. This choice was deemed more clinically relevant, es-
pecially for low dose regions, for which reporting the differ-
ence from the local dose can overstate the clinical impor-
tance of the deviation. For the high dose low gradient regions
in the target, the average difference between the measured
and planned doses, expressed as a ratio to the prescribed
dose and averaged over all tests and institutions, was
−0.0020.022, corresponding to a confidence limit mean
+1.96 of 0.045. 94% of the results fell within the confi-
dence limit. The average of the absolute value of the ratio
was 0.009.
For the low dose avoidance structures, the average differ-
ence between the measured and planned doses, expressed as
a ratio to the prescription dose and averaged over all tests
and institutions, was 0.0060.030, corresponding to a con-
fidence limit of 0.064. However, this result is skewed by a
single number coming from institution J, which had much
larger variations that were attributed to the presence of high
dose gradients. For the low dose region in the prostate case,
J reported a difference ratio of 0.142, more than twice the
difference in any other cases. Repeat measurements with the
− plan dose /prescription dose, averaged over the
Test Location M
Multitarget Isocenter
Prostate Isocenter 
Head and neck Isocenter 
CShape easier 2.5 cm anterior to isocenter 
CShape harder 2.5 cm anterior to isocenter 
Overall combined 
Confidence limit= mean+1.96
TABLE VIII. High dose point in the PTV measured with ion chamber: m
measured at each institution, with associated confidence limits.
A B C
Mean 0.004 0.012 0.006
Standard deviation  0.023 0.021 0.011
Local confidence limit mean+1.96 0.049 0.053 0.028
Number of measurements 6 6 5Medical Physics, Vol. 36, No. 11, November 2009chamber shifted by 1–2 mm produced better agreement. Dis-
carding that single result changed the overall average differ-
ence between the measured and planned doses to
0.0030.022, corresponding to a confidence limit of 0.047,
similar to the result for the high dose regions. With that
change, 91% of the results fell with the confidence limit.
Before the change, 98% of the points fell within the larger
confidence limit. The average of the absolute value of the
ratio was 0.011.
III.B.3. Composite film measurements
Seven of the nine facilities analyzed films exposed within
the phantom, although not all seven did each of the sug-
gested planes. These institutions all had their film dosimetry
normalized to a point or to an area that corresponds to ion
chamber measurement. The results are presented in Tables
XI and XII. For the high dose planes, the percentage of
points passing the gamma criteria, averaged over all tests and
institutions, was 96.64.1. For the low dose planes, the per-
centage of points passing the gamma criteria, averaged over
all tests and institutions, was 96.14.8. Combining all the
film planes gives an average of 96.34.4. Using the same
approach to establishing a confidence limit but recognizing
that it is the reduction from 100% of points passing that is
important leads to a somewhat different formulation: 100
−mean+1.96 is the percentage less than 100 that consti-
tutes the limit. This gives a value of 12.4, or 87.6%. 93% of
the film results reported gamma pass rates of 88% or higher.
Note that this formulation may not correspond to the 95%
confidence level associated with a two-tailed Gaussian dis-
tribution but is nevertheless used here as a reasonable
method to compare results.
utions, with associated confidence limits.
Standard deviation  Maximum Minimum
0.017 0.030 0.020
0.016 0.022 0.026
0.013 0.011 0.036
0.028 0.038 0.059
0.036 0.054 0.061
0.022
0.045
ed dose− plan dose /prescription dose, averaged over all the test plans
Institution
D E F G H I J
0.007 0.017 0.002 0.013 0.014 0.009 0.008
0.004 0.014 0.012 0.044 0.004 0.030 0.019
0.015 0.044 0.026 0.098 0.022 0.068 0.044
6 5 3 5 6 6 5instit
ean
0.001
0.001
0.010
0.001
0.001
0.002
TABLE IX. Low dose point in the avoidance structure measured with ion chamber: measured dose
mber
5367 Ezzell et al.: Report from AAPM Task Group 119: IMRT commissioning 5367III.B.4. Per-field measurements
Seven facilities did field-by-field measurements. Five
used a diode array MAPCHECK, Sun Nuclear Corporation,
Melbourne, FL, one used film, and one used EPID. All used
gamma criteria of 3%/3 mm. Tables XIII and XIV present
the average percentage of points passing the gamma criteria
for the different institutions and test cases. As was done for
the composite film measurements, the confidence limit here
is expressed as the reduction from 100%. The overall results
are 97.92.5, leading to a confidence limit of 7.0 or 93.0%.
94% of the per-field results reported gamma pass rates of
93% or higher.
IV. DISCUSSION
IV.A. Test suite
The test suite is a useful starting point but it is neither
comprehensive nor necessarily representative of a particular
clinic’s practice. The suite uses only 6 MV, for example. The
head and neck case has a PTV volume that is relatively large,
such as for a postoperative treatment, while clinical cases
often have multiple targets prescribed to different doses.
None of the test cases represent the broad targets found in
pelvic cases in which lymph node chains are targeted and
bowel is to be spared. Facilities should create mock clinical
cases that reasonably represent the types of cases that they
see in clinical practice, including tests of other energies if
used.
IV.B. Planning results
The planning results demonstrate that the various institu-
tions were able to produce comparable plans. The purpose of
the study was not to compare planning results but to test how
− plan dose /prescription dose, averaged over the
Test Location M
Multitarget 4 cm inferior to isocenter 
Prostate 2.5 cm posterior to isocenter
Head and neck 4 cm posterior to isocenter
CShape easier Isocenter
CShape harder Isocenter
Overall combined
Confidence limit mean+1.96
TABLE X. Low dose point in the avoidance structure measured with ion cha
test plans measured at each institution, with associated confidence limits.
A B C
Mean 0.006 0.010 0.00
Standard deviation  0.007 0.018 0.03
Local confidence limit mean+1.96 0.020 0.045 0.07
Number of measurements 5 5 5Medical Physics, Vol. 36, No. 11, November 2009well the measured doses matched those planned. The plan-
ning results needed to be comparable so that the degree of
beam modulation would likely be similar. It would be desir-
able to have measures of beam modulation to confirm that
the plans were comparable in that regard, since the level of
complexity of individual plans is related to the delivery ac-
curacy and associated quality assurance metrics. As an ex-
ample, one participating institution generated multiple head
and neck and prostate plans meeting the TG-119 planning
goals with varying complexity to evaluate the effect of plan
complexity on delivery accuracy for these standardized test
cases.
8 Plans were done with the ECLIPSE planning system.
Complexity was varied using smoothing parameters avail-
able in ECLIPSE and quantified using the number of monitor
units for delivery. Results revealed a decrease in gamma pass
rate with increasing plan complexity. While this decrease
was less than 1% for the prostate cases using both film and
MAPCHECK, measurements for the more complex head and
neck case revealed differences in gamma pass rate of ap-
proximately 3% from composite film analysis and almost 9%
from individual field measurements using MAPCHECK. Unfor-
tunately, surrogates such as the total monitor units are not
readily useful when comparing different delivery techniques,
such as sliding window, step and shoot, or tomotherapy.
Thus, selected dose-volume values were used to assess that
the plans were reasonably similar to each other.
The variation in the target dose-volume parameters was
typically less than 1.5%, except for the harder CShape test
which stipulated unachievable goals. The high dose in that
PTV exceeded the D10 i.e., dose to 10% of the volume
limit with a variation of just over 4%.
The variation in the specified dose-volume parameters to
the normal structures ranged from 2% to 20%. Doses varied
utions, with associated confidence limits.
Standard deviation  Maximum Minimum
0.019 0.014 0.050
0.018 0.030 0.025
0.024 0.061 0.017
0.024 0.050 0.037
0.025 0.055 0.021
0.022
0.047
: measured dose− plan dose /prescription dose, averaged over all the
Institution
D E F G H I J
0.013 0.005 n/a 0.005 0.008 0.008 0.045
0.006 0.013 n/a 0.005 0.024 0.014 0.021
0.024 0.030 n/a 0.014 0.056 0.036 0.086
5 5 1 5 5 5 4instit
ean
0.008
0.000
0.004
0.010
0.009
0.0036
4
2
TABLE XI. Composite film: Percentage of points passing gamma criteria of 3%/3 mm, averaged over the institutions, with associated confidence limits.
3%/
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very difficult to meet. In some cases, such as for the Bladder
D30 for the prostate plan, the dose limit was easy to satisfy
and so the actual dose could vary without penalty. Some
planners forced the dose as low as it could go without com-
promising other goals, while others did not. At the other
extreme, the harder CShape, dose goal to the core critical
structure could not be met and the actual dose achieved de-
pended on the choices made by the planner and the capabili-
ties of the planning and delivery system. In order to reduce
the variability in the planning results, additional plan goals
and indications of priority would need to be specified.
IV.C. Ion chamber results
For the target regions, each institution’s average ion
chamber measurements were within 2% of the planned dose.
Four of the nine institutions had at least one measurement
that differed from planned by more than 3%. Facility G’s
results for the two CShape cases were 6% less than planned
and that for the prostate and multitarget cases 2.2% and 3.0%
more than planned, respectively, for a mean of 1.3% but a
standard deviation of 4.4%. On the other extreme, facility D
was more consistent with a mean of 0.7% and standard
deviation of 0.4%. The confidence limit for the combined
group for these measurements in the high dose, low gradient
region was 4.5%.
For the lower dose measurements in the avoidance struc-
ture regions, eight of the nine facilities reported average dose
within 2% of planned where the percentage is of the pre-
scription dose, not the local dose with standard deviations of
Test Location Mean Standa
Multitarget Isocenter 99.1
Prostate Isocenter 98.0
2.5 cm posterior 93.2
Head and neck Isocenter 96.2
4 cm posterior 97.6
CShape easier Isocenter 97.6
2.5 cm anterior to isocenter 93.9
CShape harder Isocenter 94.4
2.5 cm anterior to isocenter 93.0
Overall combined 96.3
Confidence limit= 100−mean+1.96
TABLE XII. Composite film: Percentage of points passing gamma criteria of
A B
Number of film planes 9 9 4
Mean 99.5 92.6 99
Standard deviation  0.4 4.3 0
Local confidence limit 100−mean+1.96 1.298.8% 15.784.3% 0Medical Physics, Vol. 36, No. 11, November 2009the same magnitude. The confidence limit for the combined
group for these measurements in the low dose, avoidance
structure was 4.7%.
Based on these collective results, it seems reasonable to
expect that an institution’s average agreement between pre-
dicted and measured doses measured with an ion chamber
should certainly be at least within 3% of prescription dose.
Most of the participants in this study reported averages
within 1.5% of expected from the treatment plan. Some out-
liers were seen but few outside the confidence limits deter-
mined by this group. To be quantitative, an institution can
calculate its own confidence limit with this methodology, and
the result should be comparable to this group’s. The confi-
dence limit for the group was obtained by combining many
measurements. A single institution performing only the tests
in this test suite will have weaker statistics that could be
improved with more repetitions, either of the same tests or
similar ones derived from clinical plans. However, if the con-
fidence limit derived from the test suite is much larger than
the group’s as for facility G, for example, then it is likely
that the IMRT system can be improved before clinical treat-
ments commence.
IV.D. Composite film measurements
The first point of interest regarding the composite film
results is that two of the nine facilities did not report any.
The increasing prevalence of digital imaging and decreasing
availability of well-maintained film processors is making it
more difficult to accomplish planar dose measurements in
phantom. This is a concern, because it is important to know
viation  Maximum Minimum Number of submissions
9 100 97.5 8
24 99.8 94.2 7
6 99.9 85 3
0 100 92.4 8
5 98.9 95.6 4
9 100 88.9 7
0 99.6 87.9 5
0 99.4 86.2 5
2 99.9 81.3 5
4
12.4 i.e., 87.6% passing
3 mm, averaged over the test plans, with associated confidence limits.
Institution
E F G I J
7 4 9 5 5
97.6 98.0 93.0 95.8 97.5
2.3 1.1 6.5 3.6 2.9
.4% 6.993.1% 4.595.5% 19.780.3% 11.288.8% 8.291.8%rd de
0.
2.
7.
3.
1.
3.
5.
6.
7.
4.D
.9
.3
.699
TABLE XIII. Per-field measurements: Average percentage of points passing the gamma criteria of 3%/3 mm,
the g
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predicted distribution within the geometric shape of the
phantom. It is not possible to assess the accuracy of the
cumulative doses by only analyzing the dose distribution for
each field in a geometry radically different from the
phantom/patient. The commissioning process needs to test all
the components of the planning and delivery system, as com-
ponents and as an integrated system. Certainly, if the gantry
is maintained in a vertical direction for the individual field
measurements, then problems with delivery with different
orientations with respect to gravity will not be found. Issues
with transmission through couch support assemblies would
also not be identified without doing composite measure-
ments, and this might be relevant if gantry angles are used
for IMRT that were not used for 3D conformal plans.
If a facility cannot perform reliable planar dosimetry in
phantom, then a larger set of individual point doses needs to
be measured, but that is not the recommended solution. Fa-
cilities that are losing or have lost the ability to do film
dosimetry with radiographic film should be moving to alter-
natives such as radiochromic film,9 computed radiography
plates,10 and detector arrays with attendant scanning and
analysis tools.
For each of the six facilities performing film dosimetry,
the average percentage of points passing the gamma criteria
exceeded 90%, where the average is over all the analyzed
planes. Combining all the results gives an overall average of
96.4% with a standard deviation of 4.3%. Facilities B and G
reported more variation than did the others. Facility B re-
ported their test of the reference band case as having 99.9%
points passing, so its results for the IMRT test cases are not
likely to be heavily influenced by film dosimetry problems.
averaged over the institutions, with associated confid
Test Mean
Multitarget 97.8
Prostate 98.6
Head and neck 98.1
CShape easier 97.4
CShape harder 97.5
Overall combined 97.9
Confidence limit= 100−mean+1.96
TABLE XIV. Per-field measurements: Average percentage of points passing
confidence limits.
A B
Measurement device Diode array Diode array
Mean 98.9 93.3
Standard deviation 1.5 1.5
Local confidence limit 100−mean+1.96 3.9 96.1% 9.5 90.5%
Number of studies 5 5Medical Physics, Vol. 36, No. 11, November 2009Facility G did not report results for the band case, so one
cannot assess the film dosimetry accuracy. The confidence
limit for these collective results was 12%, which indicates
that the percentage of points passing the gamma criteria
should be more than 88% approximately 95% of the time.
For our collective results, 93% of the tests fell within the
confidence limit.
The reported percentage of points passing gamma criteria
depends heavily on the details of the implementation of the
data analysis. Examples include using a region of interest or
a threshold to exclude some points from assessment, normal-
izing the measurements to some reference point, and defining
the percentage agreement in terms of local dose or prescrip-
tion dose. In practice, physicists use commercial tools that
have different available options, and so it is difficult to offer
definitive guidance regarding acceptance levels for gamma
analysis results. It seems reasonable, however, to expect that
if one normalizes the film results to ion chamber measure-
ments in the high dose region on the same plane, then on
average about 95% of the points on the plane within the
region of interest should pass gamma criteria of 3%/3 mm
with a confidence limit that ranges down to 88%.
IV.E. Per-field measurements
Five of the seven facilities that performed this test used
the same model of dosimeter and software and so the analy-
sis could be standardized. Doing so is important in order to
compare results, because the percentage of points passing the
gamma criteria can change dramatically depending on the
details of the analysis.
limits.
andard deviation  Maximum Minimum
3.5 99.8 90.8
2.4 100 93.3
2.0 100 94.2
2.8 99.8 93.0
2.6 99.9 94.0
2.5
7.0 i.e., 93.0% passing
amma criteria of 3%/3 mm, averaged over the test plans, with associated
Institution
C D E F H
EPID Diode array Diode array Film Diode array
99.4 99.2 98.6 99.6 96.8
0.4 1.3 1.5 0.3 2.5
.3 98.7% 3.4 96.6% 4.3 95.7% 1.0 99.0% 8.1 91.9%
5 5 4 4 5ence
St1
Two of the institutions used film or EPID as the device for target and the organ at risk. For this group of facilities, the
5370 Ezzell et al.: Report from AAPM Task Group 119: IMRT commissioning 5370assessing per-field quality. Such devices have greater spatial
resolution than an array of diodes or ion chambers. These
two institutions reported average gamma pass rates that ex-
ceeded 99%, which was generally larger than those from the
diode array. This study does not provide enough data to in-
dependently derive confidence limits for film or EPID per-
field measurements, but it is reasonable to assume that these
should not be worse than the combined results reported here.
With the gamma analysis parameters used in this study,
the average percentage of points passing the criteria was
quite high: the overall average was 97.9% with a standard
deviation of the average of 2.5%. This corresponds to a
confidence limit of 7.0%, which means that the percentage of
points passing the criteria should exceed 93% approximately
95% of the time. For our collective results, 94% of the tests
fell within the confidence limit.
IV.F. Overall comments
This test protocol asks for both composite planar dosim-
etry in phantom and per-field measurements. The task group
recommends that both be done whenever possible at the time
of commissioning, because the information provided is
complementary. Composite delivery checks that the doses
add together as planned, but it is possible that the magnitude
of deviations with some beam angles could be suppressed
when combined with the other fields. Checking each field
individually on a plane perpendicular to the beam permits
that beam’s delivery to be analyzed in detail but does not
assure that the beams combine appropriately. Multiple ion
chamber measurements may substitute for composite planar
dosimetry if necessary.
The task group also cautions against relying solely on
per-field gamma analysis. When a beam is highly modulated,
a gamma analysis may fail to identify some types of prob-
lems because it is possible to find some point that matches
the intended dose by searching up to 3 mm in all directions.
Per-field 2D dose measurement differs from the measure-
ment with ion chamber in that the ion chamber is normally
placed on a high dose, low gradient region where a differ-
ence from the predicted dose may be more indicative of the
change in delivered dose to the patient. The gamma passing
rate with a 2D array may not directly reflect a dose scaling
factor error since it compares not only the scale of the dose
but also the distance between agreement points. The gamma
values depend on the data analysis method and criteria used
as well.11 If, for example, per-field QA is based on the Van
Dyk gamma criterion that is normalized to the maximum
dose as the default,12 some errors could be hidden such as
those from the MLC transmission factor, tongue and groove
effect, and dose calibration. Another viable option is to com-
bine gamma analysis and the average percentage error of all
the measured points with a predefined threshold.13
Each of the facilities participating in this comparison had
passed the RPC credentialing tests with its IMRT head and
neck phantom.14 That phantom uses TLDs to assess dose and
radiochromic film to assess the dose gradient between theMedical Physics, Vol. 36, No. 11, November 2009average agreement of the dose measured by TLDs in the
target regions with the planned dose was 0.4% with a stan-
dard deviation of 2.6%. For the TLDs in the organ at risk, the
average agreement was 1.4% with a standard deviation of
18.8%. This percentage is of the local dose, not the prescrip-
tion dose. The predicted doses in the PTV region averaged
7.13 Gy and the predicted doses in the avoidance structure
averaged 2.77 Gy. The average displacement of measured
isodose lines in the gradient region from the planned posi-
tions was 1.1 mm with a standard deviation of 1.3 mm.
These data provide independent confirmation of the accuracy
of the IMRT planning and delivery by these facilities.
The data in this report would be stronger if 1 more fa-
cilities had reported the results of the preliminary band test
in a consistent fashion and 2 if there were repetitions of the
measurements at each facility to assess the reproducibility of
the results. Those facts, along with the uncertainty in the
details of the various gamma analyses, make it difficult to
put error bars on the results and therefore draw stronger con-
clusions about the agreement between plan and measurement
that should be expected. Nevertheless, these data should be
helpful for institutions assessing their own IMRT commis-
sioning. Additionally, independent verification using IMRT
phantoms available through the RPC is always prudent.
IV.G. An example of the practical utility
of the tests
Institution B used these sets of tests as part of the com-
missioning evaluation of the beam modeling for one newly
installed linear accelerator with multiple photon energies.
The following paragraphs briefly describe key elements of
the commissioning process and illustrate how using these
tests identified that the commissioning needed to be im-
proved for one beam energy and how the main source of
error was identified.
The commissioning process for the synergy S system in-
cluded collections of a complete set of scan and point mea-
surement data for photons and electrons as specified by the
CMS/XIO beam modeling guide for the beam modulator.
Beam data collection and calibration were internally verified
by at least two independent measurements and checked
against standard data sets. Treatment planning system mod-
eling followed the guidelines of TG53.15 When compromises
had to be made, the best fits were chosen for situations mim-
icking IMRT. Before actual clinical implementation, periodic
QA baselines were established, and site specific IMRT plans
and QA measurements were performed on phantoms. QA
measurements of 3D conformal plans achieved the following
agreement statistics: 3 mm DTA, 3% difference, and pro-
duced pass rate of 97.8% average 2.6% STD.16
In the initial testing of these sets of IMRT plans and mea-
surements, however, a larger than expected discrepancy was
observed for the prostate plan with one of the photon beams
10 MV. The field-by-field analysis of diode array measure-
ments yielded an average gamma pass rate of 80.5% with 3
mm DTA and 3% dose difference.
When faced with such a finding, the clinical physicist made in the PTV and the avoidance structure, and film mea-
5371 Ezzell et al.: Report from AAPM Task Group 119: IMRT commissioning 5371must consider various reasons for the discrepancy. The re-
ported sources of deviation between planned and measured
doses fall into the following three major categories, treat-
ment planning system major source, close to 50%, delivery
system, and measurement process.3,17
For the treatment planning systems, there could be inac-
curate data input, inaccurate/insufficient modeling one ex-
ample is given in Sec. IV H, and software glitches. Com-
plexity of the IMRT plans may exacerbate the above
mentioned inadequacies. For the delivery system, there could
be output inaccuracy, beam definition system error e.g.,
MLC error, or error in patient positioning system. For the
sources in measurement process, there could be suboptimal
measurement techniques, limitation/inaccuracy in measure-
ment devices, human error in execution process. The uncer-
tainties due to some of the factors described above were
quantified in the dose distributions.18,19
In this case, the parameters that constitute beam models
for the superposition/convolution algorithm were closely
evaluated, including energy spectrum, build-up electron con-
tamination, Gaussian parameters for profile tail modeling,
transmissions of beam modifiers, and penumbra modeling
for beam modifiers. These factors were found to have signifi-
cant influence upon the dosimetric outcome from treatment
planning systems.20,21 Perturbations were applied to the en-
ergy spectrum, Gaussian parameters, and transmission fac-
tors of multileaf collimators, without significantly affecting
the fitting of the measurements during the modeling process.
Corresponding dose distributions were created to be com-
pared with measurements for IMRT plans. It was found that
gamma passing rates given certain DTA and percentage dose
deviation were most sensitive to MLC transmission factors.
By decreasing the MLC transmission from 3% to 1.5% for
the 10 MV beam, average gamma passing rate for the pros-
tate IMRT plan QA changed from 80.5% to 93.3% 3 mm
DTA, 3% dose difference. Adjustments were therefore made
to corresponding beam modeling parameters to improve the
agreements for IMRT QA measurements, keeping similar fit-
ting performances for the modeling process. Subsequent do-
simetric testing using this suite of IMRT tests and other tests
of 3D conformal beams demonstrated improved correspon-
dence between calculation and measurement for the IMRT
cases and continued agreement for the 3D conformal cases.
IV.H. Comparison to other work
In 2005, Gillis et al. published the results of a similar
study conducted in Europe.22 Eight European institutions
planned and delivered an IMRT treatment to a horseshoe-
shaped PTV surrounding a central avoidance structure in an
idealized pelvic phantom, a geometry similar to that used in
the CShape tests in this study. A variety of planning and
delivery systems were used. 95% of the PTV volume was to
receive at least 99% of the prescription dose and no more
than 1% of the avoidance structure was to receive 70% of the
prescription dose. The avoidance structure was separated
from the PTV by 1 cm. Ion chamber measurements wereMedical Physics, Vol. 36, No. 11, November 2009surements were made in seven axial planes. The chamber
results were used to adjust the film calibration. The films
were processed and analyzed at one facility to improve con-
sistency and were analyzed using gamma criteria of 3 mm
DTA and 4% dose agreement. The overall average difference
between the measured and the planned doses to the PTV,
expressed as a ratio to the planned dose, was −0.0140.017.
The mean dose to the avoidance structure was 53% of the
prescription dose, and the overall average difference between
the measured and the planned mean doses to the avoidance
structure, expressed as a ratio to the prescription dose, was
0.0000.020. Thus, the European group’s dose results were
similar to the ion chamber results from this study. The Euro-
pean group summarized their gamma index results in terms
95th percentiles. Overall, the gamma index representing the
95th percentile was 0.840.28. For their tests, at least 95%
of the points in the PTV and the avoidance structure passed a
gamma test using 3 mm DTA and 4% dose. Thus, the Euro-
pean study provides additional corroboration for the degree
of agreement to be expected for a properly commissioned
IMRT system.
A recent ESTRO booklet on “Guidelines for the Verifica-
tion of IMRT”17 summarizes the experience of several Euro-
pean institutions. It also discusses the use of confidence lim-
its as expressed here. They recommend tolerance limits of
3% for ion chamber measurement in target areas and ac-
tion limits of 5% for point dose verification.
IV.I. Confidence limits and action levels
This study has focused on IMRT commissioning, not on
per-patient quality assurance tests. In this context, the group
data have been used to develop confidence limits to assist in
judging the adequacy of IMRT commissioning. A confidence
limit is a statistical term, and its application requires the
acquisition of a reasonable number of data points. Thus, this
task group report recommends that measurements of a suite
of IMRT tests be performed, mimicking the range of cases
that will be encountered in practice. The average and stan-
dard deviation of the results can be used to compare with
those obtained by this group. The confidence limit obtained
by the local facility can be compared to this group’s as given
at the bottom of Tables VII, IX, XI, and XIII. The local
confidence limit should be on the same order or less than this
group’s. If it is much larger, then that is an indication that the
local IMRT system is not commissioned as well as it could
be. However, that conclusion presumes that the analysis has
been performed in a comparable manner and that the number
of tests is sufficient to warrant a statistical judgment. Even
though the 1.96 multiplier used in the confidence limit cal-
culation strictly applies when a very large number of samples
is available, we have chosen to use it to be clinically conser-
vative instead of using a numerically larger multiplier con-
sistent with a smaller sample size. Repetition of these tests is
suggested in order to enlarge the sample size and make the
statistical judgment more reliable. The number of test cases structure sets from http://www.aapm.org/pubs/tg119/
5372 Ezzell et al.: Report from AAPM Task Group 119: IMRT commissioning 5372can also be enlarged by using contours and dose goals from
the local practice.
This approach to testing and analysis is not limited to
6MV, although the specific results from this study were for
that energy. It would be reasonable to assume that similar
confidence limits should hold for higher energies, but that
remains to be proven.
The confidence limit does provide a mechanism for deter-
mining reasonable action levels for per-patient IMRT verifi-
cation studies. If the confidence limit is established with
enough points to provide good statistics, then using the value
of 1.96 suggests that variances in excess of the limit may
occur about 5% of the time one can decide on a higher or
lower potential action triggering percentile by using a x
value, where x can be larger or smaller than 1.96. For this
group, the confidence limit for ion chamber measurements in
the target region was 4.5% and for the low dose region was
4.7%. Thus, the recommendations of Palta et al.5 are consis-
tent with this result: For point dose measurements they rec-
ommended an action level of 5% in a high dose, low gra-
dient region and 7% in a low dose, low gradient region.
This work provides additional support for action levels ex-
pressed in terms of percentage of points passing gamma cri-
teria of 3%/3 mm: 90% for per-field measurements and
88%–90% for composite irradiations analyzed with radio-
graphic film. As noted above, however, the results of a
gamma analysis depend heavily on the details of the imple-
mentation, so these recommendations must be considered in
conjunction with the specific method used here.
In practice, one would expect that simple cases e.g.,
prostate would rarely approach these limits, but highly
modulated cases e.g., perispinal might exceed it if the sys-
tem was pushed beyond its capabilities. Thus, this type of
examination of the IMRT commissioning accuracy provides
a baseline for the initial assessment of per-patient verifica-
tion. A full discussion of per-patient quality assurance is be-
yond the scope of this report, but careful commissioning is a
prerequisite for quality treatments.
V. CONCLUSION
Treatment planning and delivery in radiation therapy are
never perfect, and so the practical question is “how good is
good enough?” This study has not attempted to answer that
question in a rigorous way but instead has studied the ques-
tion “what is a reasonable and achievable standard for IMRT
commissioning?” To provide a basis for that judgment, a
group of institutions that have passed the RPC IMRT creden-
tialing used a suite of standardized test cases to determine the
degree of agreement achievable with their planning and de-
livery systems. These results, summarized at the bottom of
Tables VII, IX, XI, and XIII, can be used as a practical
baseline for comparison by other facilities as they evaluate
their own IMRT commissioning. Facilities interested in using
this test suite can download the DICOM-RT images andMedical Physics, Vol. 36, No. 11, November 2009default.asp along with a detailed description of the planning,
measurement, and analysis process.
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